Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Lakewood-Amedex Biotherapeutics Inc.

Tracked across 2 events · 14 articles · First seen Jun 26, 2026 · Last active Sep 21, 2026

Sentiment
12
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 25
Tech
Lakewood-Amedex Biotherapeutics Inc. announced that it has obtained central and all site Institutional Review Board (IRB) approvals and confirmed clinical trial site readiness to commence its Phase 2a clinical trial of its lead product candidate…
Impact: The company is the sole actor in this event, securing IRB approvals and site readiness for the Phase 2a Nu-3 trial in infected diabetic foot ulcers. The milestone advances its lead Bisphosphocin candidate and modestly improves its clinical and financing narrative.
Sep 18, 2026 · 8 articles
2 0
Business
Impact: Lakewood-Amedex Biotherapeutics Inc. was one of the presenting companies at the Life Sciences Virtual Investor Forum.
Jun 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lakewood-Amedex Biotherapeutics Inc. live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.